Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eli Lilly and Company
Woman Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A study comparing gemcitibine and carboplatin with or without LY2228820 for women with ovarian cancer
Phase 1b - to determine the recommended Phase 2 dose of LY2228820 that can be safely administered with gemcitabine and carboplatin Phase 2 - to compare the progression-free survival in patients treat...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
An Individualized treatMent aPproach for oldER patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus
The primary objective of this study is to assess the relative success of Strategy A as compared to Strategy B in achieving and sustaining glycemic control in the absence of episodes of clinically sign...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A Phase 2 study of ALIMTA in solid tumor patients with stable third-space fluid
The primary objective of this Phase 2 study is to evaluate the safety of pemetrexed in patients with third-space fluid (pleural effusions or ascites).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A Crohn's Disease study
To test the hypothesis that treatment with LY3074828 is superior to placebo in the proportion of subjects with endoscopic response at Week 12, defined as 50% reduction from baseline in SES-CD Score
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
A study in men with low testosterone to measure the effect of testosterone solution on testosterone levels, sex drive and energy
The primary objective of the double blind phase is to compare the effect of testosterone solution vs. placebo on the proportion of hypogonadal men having a serum total testosterone concentration withi...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
An Open Label Single Arm Phase 1b/2 Study with Pharmacokinetic Sampling to Evaluate LY2181308 in Patients with Advanced Hepatocellular Carcinoma
Main objective : Phase 1b: To determine the recommended dose for the Phase 2 portion of this trial for patients with advanced hepatocellular cancer (HCC) with no other standard curative or palliativ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Eli Lilly and Company
Update Il y a 4 ans
Étude I4T-MC-JVDL : étude de phase 1 évaluant la tolérance d’un traitement par osimertinib, un inhibiteur d’EGFR, associé au ramucirumab, un anticorps anti-VEGFR-2 ou au nécitumumab, un anticorps anti-EGFR, chez des patients ayant un cancer du poumon non à petites cellules avancé présentant une mutation de l'EGFR T790M. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Le cancer du poumon, 4ème cause de cancer en France, peut prendre deux formes : « à petites cellules » ou « non à petites cellules », ce dernier représentant la forme la plus fréquente. Le récepteur a...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Phase 3, multicenter, long-term extension study of 104 weeks in patients with axial spondyloarthritis
To evaluate in patients having achieved a state of sustained remission whether the ixekizumab treatment group is superior to the placebo group in maintaining response during the randomized-withdrawal ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eli Lilly and Company
Update Il y a 4 ans
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock
To demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28 day all-cause mortality in adult patients with septic shock ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eli Lilly and Company Limited
Update Il y a 4 ans
A Phase 1b/2 Multiple-Dose Safety and Pharmacokinetic/Pharmacodynamic Study of LY2189102 in Patients with Rheumatoid Arthritis
To examine the safety and tolerability of LY2189102 administered as multiple intravenous (IV) doses to Rheumatoid Arthritis (RA) patients who are receiving stable doses of Methotrexate (MTX).
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next